Category Archives: Biotechnology

The 63 rating InvestorsObserver gives to Oncolytics Biotech, Inc. (ONCY) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, ONCYs 63 overall rating means the stock scores better than 63 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Oncolytics Biotech, Inc. (ONCY) stock is lower by -2.7% while the S&P 500 has gained 0.33% as of 3:18 PM on Friday, Jan 8. ONCY is lower by -$0.07 from the previous closing price of $2.60 on volume of 1,437,755 shares. Over the past year the S&P 500 has gained 16.55% while ONCY is lower by -36.75%. ONCY lost -$0.82 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Oncolytics Biotech, Inc. (ONCY) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the original post here:
Is Oncolytics Biotech, Inc. (ONCY) The Right Choice in Biotechnology? - InvestorsObserver

RFI

The six were injured in anexplosion on Friday in the volatile "Three Borders" region between Mali, Burkina Faso and Niger.They were taken to the military hospital in the northern Malian city of Gao, and three of them will return to France over the weekend. The six, all members of the French Barkane anti-Islamist operation, were injured in the explosion of a car bomb, reportedly driven by a suicide attacker.The officialmilitary statement says the French soldiers were on board an armoured personnel carrier, patrolling with members of the Malian armed forces.The convoy was approached by an unidentified vehicle driven at high speed, and the French manouvred to block the road to protect other members of the group.The driver of theunidentified vehicle then set off an explosion.None of the six injured soldiers is seriously hurt, although three of them are to be repatriated on Saturday for further medical treatment.This is the third attack to target French peacekeepers in Mali since the end of December, with five soldiers losing their lives. Three French soldiers killed in operation in MaliControversy continues over French airstrikeFrance's military has also announced that troops havereturned to the scene of an airstrike in central Mali to confirm that only jihadists had been targeted. This follows claims by locals thata wedding had been hit.Controversy erupted over the operation after several residents of the remote village of Bounti said that up to 20 people had been killed in theattack lastSunday. France says dozens of jihadists killed in weekend Mali air strikeOn Friday morning "a land mission made up of Barkhane soldiers went to the scene of the French strike carried out on 3 January, north of the village of Bounti", the military said in a statement."The information gathered during this mission is in all respects consistent with the analysis and assessment of the situation produced so far," the Barkhane statement added.Contradictory claims surroundhelicopter attackSeveral villagers had told the AFP news agency that a wedding party in Bounti came under fire on Sunday from a single unidentified helicopter.A cultural association that promotes Mali's Fulani ethnic group said that around 20 civilians were killed. Africa Calling Podcast: a closer look at the killings in Mali and NigerThe only armed forces that carry out offensive air operations in Mali are the national military and the Barkhane force.France has said its operation did not involve a helicopter and on Thursday evening said that the available information "excluded the possibility of collateral damage".Mali's defence ministry has supported the French account, saying its information showed that "the neutralised targets were confirmed military objectives", and that "the observed surroundings did not show any wedding scene".The ministry added that an inquiry was being opened "to better understand" what had happened.

Link:
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN Group expands its US products business with the successful acquisition of Biosun...

The 45 rating InvestorsObserver gives to Alnylam Pharmaceuticals, Inc. (ALNY) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 46 percent of stocks in the Biotechnology industry, ALNYs 45 overall rating means the stock scores better than 45 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 45 means the stock is more attractive than 45 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Alnylam Pharmaceuticals, Inc. (ALNY) stock is trading at $144.75 as of 10:40 AM on Friday, Jan 8, a rise of $5.35, or 3.84% from the previous closing price of $139.40. The stock has traded between $137.72 and $145.09 so far today. Volume today is low. So far 103,431 shares have traded compared to average volume of 509,366 shares.

Click Here to get the full Stock Score Report on Alnylam Pharmaceuticals, Inc. (ALNY) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the article here:
Is Alnylam Pharmaceuticals, Inc. (ALNY) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

A rating of 80 puts Crispr Therapeutics AG (CRSP) near the top of the Biotechnology industry according to InvestorsObserver. Crispr Therapeutics AG's score of 80 means it scores higher than 80% of stocks in the industry. Crispr Therapeutics AG also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 30 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 64 would rank higher than 64 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Crispr Therapeutics AG (CRSP) stock is trading at $180.75 as of 10:23 AM on Thursday, Jan 7, a rise of $16.90, or 10.32% from the previous closing price of $163.85. The stock has traded between $169.39 and $185.43 so far today. Volume today is light. So far 888,487 shares have traded compared to average volume of 1,989,285 shares.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Go here to see the original:
Where Does Crispr Therapeutics AG (CRSP) Stock Fall in the Biotechnology Field? - InvestorsObserver

Myovant Sciences Ltd (MYOV) is around the top of the Biotechnology industry according to InvestorsObserver. MYOV received an overall rating of 77, which means that it scores higher than 77 percent of all stocks. Myovant Sciences Ltd also achieved a score of 93 in the Biotechnology industry, putting it above 93 percent of Biotechnology stocks. Biotechnology is ranked 30 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Myovant Sciences Ltd (MYOV) stock is trading at $25.07 as of 10:49 AM on Monday, Jan 4, a drop of -$2.55, or -9.23% from the previous closing price of $27.62. The stock has traded between $25.04 and $27.70 so far today. Volume today is light. So far 551,426 shares have traded compared to average volume of 1,166,838 shares.

Click Here to get the full Stock Score Report on Myovant Sciences Ltd (MYOV) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original post:
Is Myovant Sciences Ltd (MYOV) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Allbiotech, the organization that promotes the development of biotechnology and the bioeconomy in Latin America, makes a selection each year of the 100 young leaders in that branch of the region.

This 2020 three students from the National University (UNA) of the Biology career and three of the Biotechnology Engineering career of the Technological of Costa Rica (TEC), are part of those selected.

They are Mara Jos Durn, Fiorella Arias and Melissa Cerdas from TEC, and Karol Snchez, Stephanny Snchez and Joyce Estrada from UNA, who with their selection, will have the opportunity to participate in the Leaders Summit 2021.

For Cerdas, being selected as an Allbiotech leader means a whole door of opportunities to revolutionize the Bioeconomy in Latin America. The Summit allows us to unite, identify the challenges of each country and network with many other young people, which allows us to broaden our vision and bring solutions to challenges.

Each was chosen individually for their ability to use science and technology to transform the region. They were selected from more than 500 applicants from across the region. Durn participated in the IGEM 2019 Boston and is currently an intern in a Food Science venture in San Francisco, United States.

Arias was the winner of the 6th Mission Idea Contest and the IAA Award, Tokyo-Japan, and is co-founder of Orbital Space Technologies, a company that seeks to develop the first Central American experiment onboard the International Space Station, to fight against a plague that affects plantations of bananas in Panama. Cerdas is the co-founder of the biotech startup MetLess, which seeks to develop a probiotic to reduce methane emissions in dairy farming.In the case of Karol Snchez and Stephanie Snchez, they are co-founders of the Phase G1 scientific outreach initiative and bacterial study with CRISPR & Cas9. Stephanie has focused on the bioprospecting of new antimicrobials in marine fungi.

Since 2017, 12 Costa Ricans have been selected among the top 100 in Latin America.

Read the original post:
Ticas among the 100 Young Leaders of Biotechnology in Latin America - The Costa Rica News